Simona Moșescu *
* Simona Moșescu – medic primar pediatru, Spitalul Clinic Central de copii București
Abstract
Leukotriene modifiers represent the first new class of antiasthma treatment in the past 20 years. Because they are considered a first class of effective, specifically targeted asthma therapy and now are aviailable on Romanian market, it is useful to see how to position these agents in our asthma treatment armamentarium.